Introduction {#S5}
============

Airway (AW) hyper-reactivity associated with asthma and wheezing disorders represent major long-term respiratory morbidities of former preterm infants ([@R1]--[@R3]). Supplemental O~2~ and continuous positive airway pressure (CPAP) have become the primary modes of respiratory support for preterm infants with respiratory distress syndrome ([@R4], [@R5]). It has become widely accepted that supplemental O~2~ therapy (among other factors) is likely a major contributor to the pathogenesis of AW hyper-reactivity, which has been corroborated by numerous animal studies ([@R6]--[@R10]). However, virtually nothing is known about the long-term consequences neonatal CPAP (with or without O~2~ exposure) could have on the etiology of AW reactivity ([@R11]). For the purpose of the current study, we developed a novel mouse model to test the hypothesis that neonatal CPAP alone (without hyperoxia) could cause a long-term increase in AW reactivity.

Data from animal models used to investigate the effects of neonatal supplemental O~2~ therapy support the clinical findings of increased lung inflammation ([@R7], [@R12]), remodeling including alveolar simplification, and smooth muscle proliferation ([@R10], [@R11], [@R13], [@R14]). The latter would in part explain the associated increase in AW reactivity. Clinically, supplemental O~2~ and CPAP, however, are often used together, making it difficult to delineate how either intervention alone could contribute to physiological changes in lung development and pulmonary function.

In recent years, there has been a shift in NICU practice from the use of intubation and mechanical ventilation toward less invasive CPAP treatment, largely because of the baro- or volu-trauma imposed on the lung by the former mode of respiratory support ([@R15], [@R16]). Indeed, CPAP has the potential to mitigate the adverse pathophysiological effects on lung development that would otherwise be observed with mechanical ventilation. However, there are no animal studies that have investigated the effects of neonatal CPAP on AW reactivity, and the limited studies done on adults have yielded conflicting results. In adult humans with asthma ([@R17]) or sleep apnea ([@R18]), CPAP reduced AW reactivity while others have shown CPAP caused it in sleep apnea patients ([@R19], [@R20]). In 7--8 weeks old un-anesthetized ferrets, continuous (24hrs/day, 4 days) or nocturnal (12hrs/day) CPAP reduced AW responses to acetylcholine ([@R21]). Collectively, these data suggest the effects of CPAP on AW reactivity are complex and likely reflect several factors including duration, intensity and the experimental setting used to deliver pressure to the lung, as well as developmental influences. There currently is no small (e.g. rodent) neonatal animal model of CPAP available because of the major challenges associated with delivering it non-invasively. Recently, we have developed an animal model in which CPAP can be successfully administered daily and non-invasively to un-anesthetized neonatal mice for the first week of postnatal life. In this study, we tested the hypothesis that daily neonatal CPAP would elicit a long lasting increase in AW reactivity. Further, given the sex differences in the prevalence of wheezing disorders ([@R22]) and AW hyper-reactivity ([@R23]), we also investigated whether the effects of CPAP would be different between male and female mice.

Results {#S6}
=======

P8 airway reactivity to methacholine challenge {#S7}
----------------------------------------------

Airway responses to bath-applied methacholine challenge for \~8 day old male and female mice are provided in [Figure 1](#F1){ref-type="fig"}. The slope of the small (baseline AW lumen area \<4000 pixels) AW response to increasing doses of methacholine was greater in 8 day old male mice following 7 days of neonatal CPAP treatment compared to control mice, as indicated by the larger decrease in AW luminal area at higher doses of methacholine ([Figure 1A](#F1){ref-type="fig"}, p\<0.05). However, reactivity of larger AWs (baseline AW lumen area \>4000 pixels) to methacholine was not affected by CPAP ([Figure 1B](#F1){ref-type="fig"}). In contrast to male mice, neither small nor large AWs of female mice were affected by neonatal CPAP ([Figure 1C--D](#F1){ref-type="fig"}). These data suggest males are more sensitive to neonatal CPAP than females during the first week of life, and these effects are limited to the smaller AWs.

P21 airway reactivity to methacholine challenge {#S8}
-----------------------------------------------

Airway reactivity to methacholine in 3 week old mice as assessed approximately two weeks after CPAP treatment ended is provided in [Figure 2](#F2){ref-type="fig"}. Compared to control mice, 7 days of CPAP caused an increase in AW constriction to bath-applied methacholine in both male ([Figure 2A](#F2){ref-type="fig"}) and female ([Figure 2C](#F2){ref-type="fig"}) mice, as indicated by the larger decrease in AW luminal area. The augmented AW reactivity following CPAP was limited to the smaller AWs (\<7000 pixels) for both male and female mice, whereas larger AWs (\>7000) were relatively unaffected ([Figure 2B and 2D](#F2){ref-type="fig"}). Further, 4 days of CPAP treatment (between P1-4) also had a tendency to increase AW reactivity to methacholine in the small AWs, although this did not reach statistical significance from ctrl mice ([Figure 2](#F2){ref-type="fig"}).These data suggest the effects of 7 days of CPAP on smaller AWs that occurred at P8 in the males (see [Figure 1A](#F1){ref-type="fig"}) persisted for 2 weeks after CPAP treatment ended. Interestingly, CPAP appeared to elicit a delayed effect on AW reactivity of female mice until 2 weeks after CPAP treatment. In fact, the magnitude of CPAP-induced AW hyper-reactivity at P21 was similar between males and females ([Figure 3A](#F3){ref-type="fig"}) and, compared to respective control mice, both sexes were equally responsive to methacholine following CPAP ([Figure 3B](#F3){ref-type="fig"}).

Lung morphology {#S9}
---------------

To assess the long-term effects of 7days of CPAP treatment, we quantified the radial alveolar counts in P21 mice. There was a subtle (\~10%), but significant reduction in radial alveolar counts at P21, 2 weeks after CPAP treatment ended compared age-matched control treated mice ([Figure 4](#F4){ref-type="fig"}). Representative lung sections from ctrl and CPAP treated mice are also provided ([Figure 4](#F4){ref-type="fig"}).

Discussion {#S10}
==========

The principal findings of the current study demonstrated: i) daily neonatal CPAP (7days) increased AW reactivity in male mice; ii) augmented AW reactivity persisted for 2 weeks after CPAP treatment ended; iii) development of AW hyper-reactivity was delayed in females; and iv) the effects of CPAP were restricted to the smaller AWs. We used the living lung slice preparation to assess AW responses to methacholine because it is a convenient technique that circumvents the technical challenges associated with *in vivo* measurements of respiratory mechanics in very small neonates. This technique also has the advantage of allowing direct visualization of individual AWs of various sizes.

The lack of a convenient animal model has hindered our progress in understanding how CPAP could contribute to the long-term development of AW reactivity commonly seen among preterm infants. Indeed, there are major challenges associated with delivering CPAP or providing lung inflation non-invasively to neonatal animals ([@R24]--[@R27]), especially for extended periods of time (days-weeks). These prior studies have contributed substantially to our understanding of how *in vivo* lung stretch can influence pulmonary function. For the purpose of the current study, we developed a novel rodent model of CPAP which could be successfully delivered daily to neonatal mice. We have shown that even a short (1 week) period of acute (3hrs/day) neonatal CPAP can profoundly augment AW reactivity to methacholine challenge, and it persisted, at least in males, well after (2 weeks) CPAP treatment ended. However, a shorter duration of CPAP treatment (4 days) failed to significantly increase AW reactivity indicating a "dose" dependent effect of CPAP. This would be somewhat consistent with neonatal rats that received high intermittent positive pressure (IPP) while mechanically ventilated ([@R25]). As little as 6 days of high IPP increased AW reactivity compared to mice treated with low IPP, although the rats were anesthetized daily, paralyzed and mechanically ventilated. Although IPP ventilation is a different stimulus than CPAP used in the current study, these data collectively demonstrate that lung distention during the early neonatal period can cause AW hyper-reactivity.

Few neonatal animal studies have investigated the effects of CPAP on neonatal AW reactivity and its effects on adults are conflicting ([@R17]--[@R21], [@R28]). The discrepancies between these studies suggest the effects of CPAP are multifactorial and could depend on numerous factors including the duration, intensity and experimental setting in which positive pressure was delivered to the lung. Further, it was proposed that AW hyper-reactivity caused by CPAP in adults could have been facilitated by pre-existing pulmonary inflammation ([@R19]), which is further supported by an adult rat model whereby CPAP induced lung injury and pulmonary inflammation only when it was administered together with an intravenous injection of LPS ([@R29]). On the other hand, neonatal data suggests CPAP may be protective against O~2~ induced pulmonary inflammation and lung injury and improve alveolar development. In the current study, CPAP also reduced the RAC which would be consistent with a BPD morphological phenotype; however, O~2~ exposure has also been shown to cause AW hyper-reactivity and alveolar simplification so it is difficult to predict from the current data what the combined effect of CPAP and O~2~ might have on the developing lung. Specifically, whether CPAP would elicit beneficial or deleterious effects on lung function could depend on the interaction with other confounding and potentially inflammatory mediating factors. A direct translational comparison between an immature mouse lung and the preterm infant, therefore, should be done with caution as a distending pressure of 6cmH~2~O to the smaller, healthy newborn mouse lung may elicit different responses than in the larger, compromised lung of the preterm infant. Future studies should investigate the long-term effects of CPAP in combination with O~2~ and other clinically relevant scenarios to determine how their interaction might impact pulmonary development and AW reactivity.

The lung of a newborn mouse is at the saccular stage of development ([@R30]) and could be considered somewhat comparable to that of an infant born prematurely at 26--28 weeks gestation at a time when it is likely to receive CPAP treatment. The developmental immaturity of the P8 mouse lung could explain the lack of a significant response to methacholine ([Figure 1](#F1){ref-type="fig"}). The immature lung, therefore, could be more or less vulnerable to various challenges depending on its stage of development. In support of this, interleukin-1β (IL-1β) arrested alveolar development and caused AW remodeling when over-expressed exclusively during the saccular stage of development ([@R30]). These effects were less pronounced if over expression of IL-1β occurred before (the canalicular stage) or after (alveolar stage) this period of lung development, suggesting a unique window of heightened vulnerability to inflammatory insults. Thus, unique characteristics of lung development that occur exclusively during the saccular stage of development may render the lung more vulnerable to certain challenges including CPAP and other modes of lung distention.

The cause of the increased reactivity following neonatal CPAP are beyond the scope of this study. However, we noted the increased AW reactivity of P21 male mice following prior CPAP treatment was associated with a 10% reduction in alveolar counts compared to control mice. The interaction between alveolar simplification and AW hyper-reactivity would be consistent with animal models of BPD that utilize neonatal hyperoxia exposure ([@R10]). In fact, the results of the current study demonstrate that neonatal CPAP has a long-term profound effect on airway reactivity independently of hyperoxia exposure which is used routinely in animal models of BPD. A more detailed analysis of pulmonary morphology, particularly related to possible changes in the contractile mechanisms of the AWs are needed. Indeed, studies have shown proliferation and metabolic activity of immature lungs are stimulated by stretch ([@R31]) as well as inflammatory cytokine expression ([@R26]), increased smooth muscle mass, squamous epithelium metaplasia ([@R25]) and accelerated lung growth ([@R27]).

We noted the AW hyper-reactivity following neonatal CPAP was restricted to the smaller AWs, which continued to be observed even 2 weeks after CPAP treatment ended, although this effect was unique to males. This is in part consistent with the long-term increase in smooth muscle in the small conducting AWs of 10 month old mice exposed to hyperoxia (65% O~2~) during the first 7 postnatal days ([@R9]). The mechanisms determining the selective and persistent effects of CPAP on the smaller AWs remains to be determined, but suggest they may be more vulnerable to lung distention than larger AWs.

Finally, the presence of AW hyper-reactivity in male (but not female) mice at the time of CPAP treatment (P8) could indicate they are more sensitive than females, although it was interesting to note a delayed development of hyper-reactivity in the females. This is surprisingly consistent with the human literature in that preterm boys are at greater risk for BPD (and mechanical ventilation) while in the NICU ([@R32]), whereas former preterm girls tended to exhibit a higher prevalence of respiratory complications (asthma and shortness of breath during exercise) at 19 years ([@R22]). Although it's difficult to compare a 3 week old mouse formerly treated with CPAP with 19 yr old humans, it would be interesting to know how CPAP treatment persists well into adulthood for either male or female mice. Adult female mice exhibited a greater response to inhaled methacholine compared to males when treated with 4 days of hyperoxia from birth ([@R33]). Similarly, in normal healthy 6 week old male mice, AW reactivity to methacholine was greater than females, although by 12 weeks this had reversed as females became more reactive than the males ([@R23]). The cause for the delayed development in AW hyper-reactivity in female mice treated with CPAP is beyond the scope of the study, although hormonal influences are likely to play a role. Indeed, resistance to oxygen toxicity was delayed in castrated young male rats ([@R34]) whereas estrogen treatment also delayed LPS-induced lung injury and inflammation in ovariectomized female mice ([@R35]).

Conclusion {#S11}
----------

In conclusion, we have developed a novel animal model of neonatal CPAP using an awake, un-anesthetized mouse and have demonstrated that a clinically relevant level of CPAP caused a persistent increase in AW reactivity. The neonatal mouse, therefore, may be a promising model to investigate the long-term effects of CPAP on pulmonary development. Future studies should investigate how CPAP could contribute to the pathophysiology of lung function in the presence of other clinically relevant scenarios including supplemental O~2~ and/or infection. Further work is needed to understand the mechanistic pathways contributing to the AW hyper-reactivity to determine potential longer-term consequences of neonatal CPAP in preterm infants with respiratory distress syndrome.

Experimental Methods {#S12}
====================

Subjects {#S13}
--------

Time-pregnant mice (C57BL/6J) were purchased from a commercial vendor (Charles River) and were later observed to give birth in our animal facility. Mice were treated with or without CPAP in 21% O~2~ for the first week of postnatal life; the lungs were removed in preparation for the measurement of AW reactivity using the living lung slice preparation the day after CPAP ended (P7) or two weeks later (P21). All procedures were carried out in accordance with the National Institute of Health (NIH) guidelines for care and use of laboratory animals and were approved by the Animal Care and Use Committee at Case Western Reserve University.

Neonatal CPAP Treatment {#S14}
-----------------------

Following the day of birth (P0), the litter was divided in half and both male and female pups were randomly assigned to receive either CPAP or no CPAP starting the following day (P1) for the first 7 postnatal days. An example of how CPAP was delivered on the first postnatal day is provided in [Figure 5](#F5){ref-type="fig"}). The pups and the dam were maintained in a temperature controlled room during a 12:12hr, light:dark cycle and provided food and water *ad lib*. Each day the mice were removed from the dam and fitted with a custom made mask to fit snuggly around the head for administering CPAP ([Figure 5](#F5){ref-type="fig"}). CPAP was administered to unanesthetized mice, while placed on a temperature controlled heat pad (Gaymar T/pump, NY) for temperature support. The mice appeared to tolerate the mask and CPAP well and settled down quickly after an initial few minutes of restlessness. The mask was designed with an entry port to deliver a flow of humidified air, which passed through to an exit port that was connected with tubing to a downstream manometer. An adjustable leak positioned in the downstream tubing between the mask and the manometer enabled continuous flow through the mask, while also allowing fine-adjustment of CPAP to be delivered directly to the mask (and the AWs of the mouse). Adjusting the leak to reduce the air flow through the mask provided a measureable back-pressure into the mask and to the manometer, which was used to continuously monitor the amount of CPAP for the duration of treatment. Although the mask created a snug fit around the face of the animal, it was loose enough that on some occasions, the mouse was able to maneuver free, after which it was immediately repositioned on the mask. CPAP was maintained at 6cmH~2~O by adjusting the downstream leak or the upstream flow into the mask. CPAP lasted just 2hrs for the first day to minimize the duration the pups were separated from the mother, but was increased to 3hrs/session for the following 6 consecutive days (7 days total). An elaborate set up was designed to enable simultaneous delivery of CPAP to multiple mice (up to 8 at a time). Control mice were also removed from the dam, fitted with the same masks, placed on the same heat pad, received the same airflow, but did not receive CPAP. After each bout of CPAP, the mask was removed and the pups were returned to the mother to resume normal rearing. The exposure to CPAP and the application of the mask for control mice was repeated daily for 7 consecutive days from P1 through P7 ([Figure 5](#F5){ref-type="fig"}). At the end of the 7 days of CPAP, the lungs of the mice were prepared for measurement of AW reactivity the following day or allowed an additional 2 weeks of un-interrupted maternal care. AW reactivity was assessed using the *in vitro* living lung slice preparation, as described previously for mature rodents ([@R36], [@R37]). An additional group of male and female mice were also used to assess the effects of a shorter duration (4 days) of CPAP between P1-4 on AW responses to methacholine. AW reactivity in these mice was assessed at P21, approximately 17 days after CPAP treatment ended, enabling age-match comparison to the mice that received 7 days of CPAP.

Measurement of Airway Reactivity {#S15}
--------------------------------

The day after (P8) or 2 weeks after (P21) CPAP treatment ended, mice were sacrificed via anesthetic overdose (intraperitoneal injection of a ketamine/xylazine mix (100 mg/kg/10mg/kg, respectively) to prepare the lungs for *in vitro* measurements of AW reactivity to methacholine. After death was confirmed, the mouse was placed supine for cannulation of the trachea using a syringe loaded with agarose. The cannula (PE tubing, diameter: 0.5mm (P8) or 0.58mm (P21)) was inserted through a small ventral incision through the neck and into the anterior most part of the trachea. The cannula was advanced \~3mm and held securely in place with suture. Liquefied agarose (40°C) was gently injected to inflate the lungs (0.4ml for P8 mice; 0.8ml for P21 mice) and the mouse placed in the refrigerator for 30 minutes to allow the agarose to cool and gel. The entire lung was then removed, placed on a vibratome, sliced into 300μm sections, and immersed in DMEM + Pen/Strep solution for overnight incubation (5% CO~2~; 37°C) to melt the agarose. The following day, the lung slices were then rinsed in HBSS and mounted in an *in vitro* recording chamber for live imaging of AW responses to methacholine challenge.

For live imaging of individual AWs, the slices were covered with a thin lightweight sheet of mesh and a coverslip, which were held in place with silicone grease. The recording chamber containing the slice was mounted on a microscope (DMLFS, Leica Microsystems, Wetzler, Germany) and perfused (7ml/min) continuously with HBSS at room temperature using a perfusion pump (MPII, Harvard Apparatus, Holliston, MA). The microscope mounted with a camera (Rolera Fast, QImaging, Canada) was used to identify individual AWs under 5X magnification. After an initial 3 minute period of baseline, the chamber was perfused with increasing doses of methacholine and changes in AW lumen area were recorded continuously. The extent of AW constriction in response to increasing doses of methacholine (0.25, 0.5, 1, 2, 4, and 8μM) was determined at the end of a 2 minute period of exposure at each dose. Image analysis software (ImageJ software, ([@R38])) was used to determine the luminal area (in pixels) at each dose of methacholine to determine the extent of AW constriction. The greater the decrease in luminal area, the more reactive the AWs.

Individual AWs were chosen at random and the response to methacholine was performed on one AW/lung section, although we typically collected 1--2 sections per animal. Thus, treatment groups consisted typically of 1--2 AWs/animal spread across 2--3 litters. We categorized AWs into large or small size for each age group (i.e. P8 or P21) determined by averaging the largest and then the smallest AW lumen area to obtain a "middle" threshold. AWs with a baseline area above or below this value were then considered large or small, respectively (4000 luminal pixel area for P8; 7000 luminal pixel area for P21).

Radial alveolar counts {#S16}
----------------------

Radial alveolar counts were performed as previously described ([@R10], [@R38]) on 21 day old male mice. In brief, mice were euthanized with an intraperitoneal injection of ketamine/xylazine, the trachea was cannulated, and lungs were inflation-fixed (25 cm H~2~O) for 10 min with 10% neutral-buffered formalin. The left lung was removed, prepared for immunostaining, post fixed for two days at 4°C and paraffin embedded. Sections were stained with hematoxylin and eosin, and alveolarization was assessed by performing radial alveolar counts. All images were obtained using a Rolera XR CCD camera (Q-Imaging, Canada) mounted on a Leica DMLB microscope (Leica Microsystems, Germany). Images were analyzed using research-based digital image analysis software (Image-pro Plus 7.0, Media Cybernetics, Silver Spring, MD). RAC was determined by counting the number of alveolar septa transected by a perpendicular line drawn from the terminal bronchiole to the nearest connective tissue septum ([@R38]), and was averaged from 8--10 sections per animal from each treatment group.

Data Analysis {#S17}
-------------

Statistical comparison of responses to methacholine between control and CPAP treated groups was made using a two-way, repeated measures ANOVA. Comparison of maximum contraction (at 8μM methacholine) between different size AWs or genders was performed using a one-way ANOVA. Statistical comparison of radial alveolar counts was performed between Ctrl and CPAP treated male mice using a t-test. Differences were considered significant at p \<0.05. All values for AW lumen area are expressed as mean ± SEM and (where relevant) presented in raw units (pixels) or as a fraction of initial baseline value.
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![Airway (AW) responses to methacholine challenge in the *in vitro* living lung slice preparation from \~8 day old (**A--B**) male and (**C--D**) female mice that received 7 days of neonatal (P1-7) CPAP (6cmH~2~O). CPAP (square symbols) increased small AW (**A**) responses to methacholine in males compared to Ctrl mice (circle symbols), whereas larger AWs (**B**) were not affected by CPAP. In contrast, neither the small (**C**) or large (**D**) AWs of female mice were affected by CPAP. Values in **A** and **C** are "small" AWs defined as a baseline lumen area \<4000 pixels; "large" AWs (**B** and **D**) defined as baseline lumen area \>4000. **B** and **D** are the response to maximum (8μM) methacholine. \*indicates significant difference in the slope of the response between Ctrl and CPAP animals (N=7--10 airways from 4--5 mice/group; p\<0.05).](nihms664596f1){#F1}

![Airway responses to methacholine challenge in the *in vitro* living lung slice preparation from 21 day old (**A--B**) male and (**C--D**) female mice that received either 4 (triangles) or 7 (squares) days of neonatal CPAP (6cmH~2~O). Note, 7 days of CPAP increased AW reactivity in small AWs of both male (**A**) and female (**C**) mice compared to control (Ctrl, circles) animals. The large AWs of both male (**B**) and female (**D**) mice were not affected by CPAP. "Small" AWs (**A** and **C**) are defined as baseline lumen area \<7000 pixels; "large" AWs (**B** and **D**) are defined as baseline lumen area \>7000 at baseline. \*indicates significant difference in the slope of the response to methacholine of Ctrl animals (N=6--8 airways from 4--5 mice/group); ^\#^indicates significant difference in the slope of the response to 4days of CPAP (p\<0.05).](nihms664596f2){#F2}

![Small AW (\<7000 pixel baseline lumen area) responses to methacholine challenge in (**A**) 21 day old male (black symbols) and female (open symbols) control mice and (**B**) the effects of 7 days of neonatal CPAP on small AW responses to maximum (8μM) dose of methacholine. AW reactivity to methacholine was similar between male and female control mice (**A**) and both sexes were equally affected by 7 days of neonatal CPAP (**B**). Values in **A** are expressed as a fraction of baseline lumen area; whereas values in **B** are expressed as absolute AW area at maximum contraction (8μM, methacholine). *Inset:* average values for the mean AW size (at baseline) for both male and female mice was not different. \*indicates significant slope of the response to methacholine (p\<0.05); however, there was no difference in the slopes between sexes, suggesting males and females are equally sensitive to CPAP treatment.](nihms664596f3){#F3}

![Average (**A**) radial alveolar counts from 21 day old male that received 7 days of CPAP (6cmH~2~O); and (**B**) representative images of a lung from a control (*top*) and CPAP (*bottom*) mouse. Note, neonatal CPAP treatment caused a subtle (10%), yet significant reduction in radial alveolar counts compared to Ctrl mice. \*significantly different from Ctrl mice (p\<0.05). Scale: 100μm.](nihms664596f4){#F4}

![Schematic of the setup used to administer CPAP non-invasively to neonatal mice. A collar is fitted over the face through which air flows to a downstream manometer. An adjustable leak allows optimization of the back-pressure (i.e. CPAP) to be applied to the mask and AWs of the mouse. The level of CPAP can be accurately measured using the manometer (ΔP, pressure difference) and adjusted accordingly. The protocol for CPAP delivery (indicated above) consisted of 6cmH~2~O, 3 hours/day, for 7 consecutive days from postnatal age 1--7 days (P1-P7). Airway responses to methacholine challenge were assessed in the *in vitro* living lung slice preparation the day after (P8) and \~2 weeks after CPAP treatment ended. Note, however, CPAP was administered for only 2 hours on the first day (P1) instead of 3hrs to minimize the duration the litter was separated from the dam.](nihms664596f5){#F5}
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